

Applicants note that claim 17 is also directed to a method of use and should be included in Group I and assume that the Examiner means to include claim 17 in Group I

Applicants elect hereby claims 10-15 directed to a method of treating diabetic diseases.

The Examiner further requires the election of a single compound from the base Formula (I).

Applicants hereby elects compound of Example 43 (pages 43-44 of the specification, wherein n is 2, z is  $-NR^{2a}R^{2b}$  (wherein R<sup>2a</sup> and R<sup>2b</sup> are methyl), X<sup>1</sup> is nitrogen and X<sup>2</sup> is a methine group.

REMARKS

Applicant is making this election without traverse in order to expedite the prosecution of this application.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: August 28, 2006

By:



Maria C.H. Lin  
Registration No. 29,323

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, NY 10154-0053  
(212) 758-4800  
(212) 751-6849

Telephone  
Facsimile